FORMULARY

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

 

04:00.00 Antihistamine Drugs

Anti-Infective Agents
08:12.02 Aminoglycosides
08:12.06 Cephalosporins
08:12.07 Miscellaneous Beta-Lactam Antibiotics
08:12.12 Macrolides
08:12.16 Penicillins
08:12.18 Quinolones
08:12.20 Sulfonamides
08:12.24 Tetracyclines
08:12.28 Miscellaneous Antibiotics

Antifungals
08:14.04 Allylamines
08:14.08 Azoles
08:14.16 Echinocandins
08:14.28 Polyenes
08:14.32 Pyrimidines
08:14.92 Miscellaneous Antifungals

Antituberculosis Agents
08:16.04 Antituberculosis Agents
08:16.92 Miscellaneous Antimycobaterials
08:18.04 Adamantanes

Antivirals
08:18.08 Antiretroviral Agents
08:18.20 Interferons
08:18.24 Monoclonal Antibodies
08:18.28 Neuraminidase Inhibitors
08:18.32 Nucleosides and Nucleotides
08:18.92 Miscellaneous Antivirals

08:30.08 Antimalarial Agents

08:30.92 Miscellaneous Antiprotozoals

08:36.00 Urinary Anti-Infectives

10:00.00 Antineoplastic Agents

Autonomic Drugs
12:04.00 Parasympathomimetic (Cholinergic Agents)
12:08.04 Antiparkinsonian Agents
12:08.08 Antimuscarinics/Antispasmodics
12:12.00 Sympathomimetic (Adrenergic) Agents
12:16.00 Sympatholytic Adrenergic Blocking Agents
12:20.00 Skeletal Muscle Relaxants
12:92.00 Miscellaneous Autonomic Drugs

16:00.00 Blood Derivatives


Blood Formation and Coagulation
20:04.04 Iron Preparations
20:12.04 Anticoagulants
20:12.08 Antiheparin Agents
20:12.16 Hemostatics
20:16.00 Hematopoietic Agents
20:24.00 Hemorrheologic Agents
20:40.00 Thrombolytic Agents

Cardiovascular
24:04.00 Cardiac Drugs
24:04.04 Antiarrhythmic Agents
24:04.08 Cardiotonic Agents
24:06.04 Bile Acid Sequestrants
24:06.06 Fibric Acid Derivatives
24:06.08 HMG-COA Reductase Inhibitors
24:06.92 Miscellaneous Antilipemic Agents
24:08.00 Hypotensive Agents
24:12.00 Vasodilating Agents
24:12.08 Nitrates And Nitrites
24:12.92 Miscellaneous Vasodilating Agents
24:16.00 Sclerosing Agents
24:20.00 Alpha-Adrenergic Blocking Agents
24:24.00 Beta-Adrenergic Blocking Agents
24:28.00 Calcium-Channel Blocking Agents
24:32.04 Angiotensin-Converting Enzyme Inhibitors
24:32.08 Angiotensin II Receptor Antagonists

Central Nervous System Agents
28:04.00 General Anesthetics
28:08.04 Nonsteroidal Anti-Inflammatory Agents
28:08.08 Opiate Agonists
28:08.12 Opiate Partial Agonists
28:08.92 Miscellaneous Analgesics And Antipyretics
28:10.00 Opiate Antagonists
28:12.04 Barbiturates
28:12.08 Benzodiazepines
28:12.12 Hydantoins
28:12.20 Succinimides
28:12.92 Miscellaneous Anticonvulsants
28:16.00 Psychotherapeutic Agents
28:16.04 Antidepressants
28:16.08 Antipsychotic Agents
28:20.00 Anorexigenics; Respiratory, Cerebral Stimulants
28:24.04 Barbiturates
28:24.08 Benzodiazepines
28:24.92 Misc. Anxiolytics, Sedatives & Hypnotics
28:28.00 Antimanic Agents
28:92.00 Misc. Central Nervous System Agents

34.00.00 Dental Agents
36.00.00 Diagnostic Agents
36.04.00 Adrenocortical insufficiency
36.32.00 Fungi
36.34.00 Gallbladder Function
36:40.00 Kidney Function
36:52.00 Mumps
36:56.00 Myasthenia Gravis
36:60.00 Thyroid Function
36:61.00 Pancreatic Function
36:68.00 Roentgenography
36:84.00 Tuberculosis
36:88.00 Urine And Feces Contents
36:88.24 PH Testing
38:00.00 Disinfectants (For Non-Dermatologic Use)

Electrolytic, Caloric, and Water Balance
40:04.00 Acidifying Agents
40:08.00 Alkalinizing Agents
40:10.00 Ammonia Detoxicants
40:12.00 Replacement Preparations
40:18.18 Potassium-Removing Resins
40:18.19 Phosphate-Removing Agents
40:20.00 Caloric Agents
40:28.00 Diuretics
40:28.10 Potassium Sparing Diuretics
40:36.00 Irrigating Solutions
40:40.00 Uricosuric Agents

44:00.00 Enzymes

Antitussives, Expectorants, and Mucolytic Agents
48:08.00 Antitussives
48:16.00 Expectorants
48:24.00 Mucolytic Agents

Ear, Eye, Nose, and Throat (EENT)
52:02.00 Antiallergic Agents
52:04.04 Antibiotics
52:04.08 Sulfonamides
52:04.12 Miscellaneous Anti-Infectives
52:08.00 Anti-Inflammatory Agents
52:10.00 Carbonic Anhydrase Inhibitors
52:16.00 Local Anesthetics
52:20.00 Miotics
52:24.00 Mydriatics
52:32.00 Vasoconstrictors
52:36.00 Miscellaneous EENT Drugs

Gastrointestinal Drugs
56:04.00 Antacids And Adsorbent
56:08.00 Antidiarrhea Agents
56:10.00 Antiflatulents
56:12.00 Cathartics And Laxatives
56:14.00 Cholelitholytic Agents
56:16.00 Digestants
56:20.00 Emetics
56:22.00 Antiemetics
56:24.00 Lipotropic Agents
56:40.00 Miscellaneous GI Drugs

64:00.00 Heavy Metal Antagonists

Hormones and Synthetic Substitutes
68:04.00 Adrenals
68:08.00 Androgens
68:12.00 Contraceptives
68:16.04 Estrogens
68:16.12 Estrogen Agonist-Antagonists
68:20.08 Insulins
68:20.20 Sulfonylureas
68:20.92 Miscellaneous Antidiabetic Agents
68:24.00 Parathyroid
68:28.00 Pituitary
68:32.00 Progestins
68:36.04 Thyroid Agents
68:36.08 Antithyroid Agents

72:00.00 Local Anesthetics

76:00.00 Oxytocics

Serums, Toxoids, and Vaccines
80:04.00 Serums
80:08.00 Toxoids
80:12.00 Vaccines

Skin and Mucous Membrane Agents
84:04.04 Antibiotics
84:04.06 Antivirals
84:04.08 Antifungals
84:04.12 Scabicides And Pediculicides
84:04.16 Miscellaneous Local Anti-Infectives
84:06.00 Anti-Inflammatory Agents
84:08.00 Antipruritics And Local Anesthetics
84:12.00 Astringents  
84:24.04 Basic Lotions And Liniments
84:24.08 Basic Oils And Other Solvents
84:24.12 Basic Ointments And Protectants
84:24.16 Basic Powders And Demulcents  
84:36.00 Miscel.Skin And Mucous Membrane Agents  

Smooth Muscle Relaxants
86:12.00 Genitourinary Smooth Muscle Relaxants
86:16.00 Respiratory Smooth Muscle Relaxants

Vitamins
88:04.00 Vitamin A
88:08.00 Vitamin B Complex
88:12.00 Vitamin C
88:16.00 Vitamin D
88:20.00 Vitamin E
88:24.00 Vitamin K Activity
88:28.00 Multivitamin Preparations

92:00.00 Unclassified Therapeutic Agents

94:00.00 Devices

96:00.00 Pharmaceutical Aids

 

 

Additions to Web Site (Date added)
Please call Marshall Pierce at 804/764/6307 and leave a message if you see anything that needs to be changed or updated.

Arixtra 12/06, Dosing Chart explanation, Therapeutic Dosing Chart Based on Dosing Weight and Creatinine Clearance, Therapeutic Dosing Based on Levels, Prophylaxis Dosing Chart Based on Dosing Weight, Prophylaxis Dosing Chart Base on Levels, Fondaparinux Pharmacokinetic Monitoring Form, & Arixtra Dosing Calculator and Data Fitting For Mid Point Levels

Arixtra levels may now be ordered. The reference lab runs the assay M-F, turn around time may be several days.  When ordering include a reminder to send a manual form since the test can not be ordered in SMS. The specimen required is to be drawn in a Blue top-citrated plasma collection tube. 7/07

Vancomycin Pharmacokinetic Dosing: Analysis of Patient Data & Optimization of Kinetic Parameters Changes to program were installed 7/3/07.

Gadolinium Contrast Agents FDA warnings and articles

Infasurf Dosing (6/07)

Ceftriaxone Safety Warning for Neonates (Letter from company, PI 5/07)
Cetriaxone should not be administered concurrently with calcium-containing solutions or products in newborns because of the risk of precipitation. Calcium containing solutions or products must not be administered within 48 hours of the last administration of ceftriaxone.
ASHP clarification

P&T/MEC allow Chemotherapy, monoclonal antibodies, and IVIG orders to be rounded up or down by 5% to the nearest vial size(s) to minimize wastage.

Epoetin/Darbepoetin (7/07)

CMS has determined that there is sufficient evidence to conclude that erythropoiesis stimulating agent (ESA) treatment is not reasonable and necessary for beneficiaries with certain clinical conditions, either because of a deleterious effect of the ESA on their underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use. These conditions include:

  1. any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis;
  2. the anemia associated with the treatment of acute and chronic myelogenous leukemias (CML, AML), or erythroid cancers;
  3. the anemia of cancer not related to cancer treatment;
  4. any anemia associated only with radiotherapy;
  5. prophylactic use to prevent chemotherapy-induced anemia;
  6. prophylactic use to reduce tumor hypoxia;
  7. patients with erythropoietin-type resistance due to neutralizing antibodies; and
  8. anemia due to cancer treatment if patients have uncontrolled hypertension.

CMS have also determined that ESA treatment for the anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma and lymphocytic leukemia is only reasonable and necessary under the following specified conditions:

  1. The hemoglobin level immediately prior to initiation or maintenance of ESA treatment is < 10 g/dL (or the hematocrit is < 30%).
  2. The starting dose for ESA treatment is the recommended FDA label starting dose, no more than 150 U/kg/three times weekly for epoetin and 2.25 mcg/kg/weekly for darbepoetin alpha. Equivalent doses may be given over other approved time periods.
  3. Maintenance of ESA therapy is the starting dose if the hemoglobin level remains below 10 g/dL (or hematocrit is < 30%) 4 weeks after initiation of therapy and the rise in hemoglobin is > 1g/dL (hematocrit > 3%).
  4. For patients whose hemoglobin rises <1 g/dl (hematocrit rise <3%) compared to pretreatment baseline over 4 weeks of treatment and whose hemoglobin level remains <10 g/dL after the 4 weeks of treatment (or the hematocrit is <30%), the recommended FDA label starting dose may be increased once by 25%. Continued use of the drug is not reasonable and necessary if the hemoglobin rises <1 g/dl (hematocrit rise <3 %) compared to pretreatment baseline by 8 weeks of treatment.
  5. Continued administration of the drug is not reasonable and necessary if there is a rapid rise in hemoglobin > 1 g/dl (hematocrit > 3%) over 2 weeks of treatment unless the hemoglobin remains below or subsequently falls to < 10 g/dL (or the hematocrit is < 30%). Continuation and reinstitution of ESA therapy must include a dose reduction of 25% from the previously administered dose.
  6. ESA treatment duration for each course of chemotherapy includes the 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.

The Following are awaiting MEC approval

 

Adverse Drug Reaction Reporting
Overview of Adverse Drug Reactions
Adverse Drug Reaction Reporting Form

FDA MedWatch and Patient Safety Program
 

Antibiograms:
 

Calculators
Arixtra Dosing Calculator
Creatinine Clearance Calculator
Drip Rate Calculator, Adult Standard
Hepatic Disease Score Calculator for Argatroban Dosing  
Pulse Dosing of Aminoglycosides
Traditional Dosing of Aminoglycosides
Vancomycin Dosing Calculator
CMS Core Indicators
Community Acquired Pneumonia CMS Criteria
DVT Prophylaxis BSR Approved Protocol

Communicate With The Pharmacy
Richmond System Pharmacy Director
Charlie Johnston, 627-5190
Directors of Pharmacy

Memorial Regional Medical Center, Anne Jones 764-6367
Richmond Community Hospital, Betty Drummond 225-1711
St. Francis Medical Center, Tulinh Le 594-7696

St. Mary's Hospital, Rebecca Shearon  287-7583
St. Mary's Hospital, Jodi Purcell 287-7011

Clinical Pharmacy Manager
Marshall Pierce, 764-6307, 287-7921

Phone List
Memorial Regional Medical Center Pharmacy Phone List

St. Mary's Pharmacy Phone List

 

Clinical Initiatives
Clinical Initiatives for Pharmacists PowerPoint Slides
Clinical Initiatives
DVT Prophylaxis
DVT Prophylaxis BSR Approved Protocol

Enoxaparin renal adjustment for creatinine clearance less than 30 ml/min

Education
Education
 
Forms
Autobstitutions With Hyperlinks
Drotrecogin Preprinted Physician Order Form
Epoetin / Darbepoetin OPIC Monitoring Form
Filgrastim  / Pegfilgrastim OPIC Monitoring Form
Formulary Addition Request Form, Non-Formulary Request Form & Non-Formulary Decision Algorithm
Opioid Equivalance Chart
Pharmacokinetic Patient Monitoring Form
Steroid Equivalence

TPN Adult & Pediatric Patients 12 years or older and 50 kg or more
Warfarin Dosage and INR Form

Fun Stuff
Adoption of a Greyhound: Cobe's Web
Grand Canyon
Greyhound Pictures
Flower Pictures
Flowers 2
Holiday Decorations
Humpback Rocks Skyline Drive Near Charlottesville, VA
Las Vegas
Steve's Hawaiian Vacation
Richmond Metro Zoo
Sunrise
Sunset
Infusion Rate Charts & IV Push List
Adult Standard Drip Rate Charts
Adult Standard Drip Rate Calculator
Pediatric Standard Drip Rate Charts
IV Push List MRMC
Vasoactive Medication Infusion Policy & Information Chart (MRMC)
IRB Protocols
 
Institute for Safe Medication Practices
IV To Oral Conversion Program
IV To Oral Conversion P&T Review
IV To Oral References
IV to Oral Conversion Form RCH
IV to Oral Conversion Form MRMC/SMH

 

Levalbuterol
Levalbuterol Conversion to Albuterol and DUE Form
 

 

 

Medication Recalls
FDA Medication Recalls, Web Site
Medication Safety
Medication Safety Page
 
Medication Shortages
Bon Secours Richmond Shortages
FDA Information on Medication Shortages
Medication Usage Evaluations
Data Collection Forms
MUE Results

 

Neonatal  
Education Series

Infasurf Dosing
NICU Pyxis Override List

Nursing Information
Nursing Information
Nutrition Services Formulary
Tube Feeding Equivalent Products
Oral Supplements
Tube Feedings

SMH-Medical Nutritional Formulary

Oncology
Education
Links

 

 

Pain Management
Pain Management
 

Patient Education Materials
Vaccine Information for the Patient
Warfarin Booklet
Patient Assistance Programs
RxAssist
NeedyMeds

Partnership for Prescription Assistance
IndiCare™
Drug Assistant

 

 

Pharmacists Memos
3/16/06
Neurontin Renal Dosing (Gabapentin-Induced Neurologic Toxicities)
Pharmacokinetic Drug Dosing
Pharmacokinetic Drug Dosing
 
Pharmacy Policy & Procedure
Postoperative Nausea and Vomiting
Prophylaxis and Treatment of Postoperative and Opioid Induced Nausea and Vomiting P&T Review
 
Protocols for Bon Secours Richmond
Acetaminophen Toxicity
Alteplase For Catheter Clearance
Argatroban for Heparin Induced Thrombocytopenia
Use of Calcium in Treatment of Hypocalemia or Hyperkalemia in Adults
Hypocalcemia
Hyponatremia
Digoxin Immune Fab
Hypophosphatemia
Tru Blue for Coloring Tube Feeding
Registered Users
Login
Student Presentations
Surgical Prophylaxis
Ancef and Vancomycin Recommended Dose
Mupirocin Nasal
Guidelines for Antibiotic Prophylaxis for GI Endoscopy
BSR Suggested Antibiotics for Prevention of Wound Infection and Sepsis in Surgical Patients
BSR Suggested Antibiotics for Prevention of Wound Infection and Sepsis In Surgical Patients: Excel Version with infusion rate and repeat intraoperative doses


 
Toxicology
Acetaminophen Toxicity
American Academy of Clinical Toxicology
Digoxin Toxicity
Treatment Guidelines

Treatment Guidelines

 

Useful Links
Agency for Health Care Policy and Research
Centers for Disease Control and Prevention
Clearing House for Health Outcomes
Clinical Studies Results
Dr Fungus
Drug Prescribing in Renal Failure
FDA
FDA Medication Recalls
FDA Information on Medication Shortages
Institute for Safe Medication Practices

Malignant Hyperthermia
Merck Manual Online
National Guideline Clearing House

Orange Book

Orange Book: Therapeutic Equivalence

Wound Care Products
Web Site Author
Marshall Pierce PharmD, Shared Services,
MRMC Tuesday, Thursday, and Friday afternoon 804/764-6307
SMH Monday, Wednesday  804/287-7921

 

Below are for testing only. Please do not use these links.

Login Page

Default Page

Create User

 

   
  Hit Counter
   

Introduction Page